Clinical Trials Logo

EGFR Exon 19 Deletion Mutation clinical trials

View clinical trials related to EGFR Exon 19 Deletion Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT01532089 Completed - Clinical trials for Stage IV Lung Non-Small Cell Cancer AJCC v7

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Start date: March 16, 2012
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well erlotinib hydrochloride (Tarceva) with or without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. Bevacizumab may also stop the growth of NSCLC by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether erlotinib hydrochloride is more effective when given alone or with bevacizumab in treating patients with NSCLC.